Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer.
Aspiration pneumonia
Chemoradiotherapy
Head and neck cancer
Radiotherapy
Risk factors
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
04 Mar 2020
04 Mar 2020
Historique:
received:
27
06
2019
accepted:
26
02
2020
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
24
10
2020
Statut:
epublish
Résumé
Aspiration pneumonia is one of the most important side effects of chemoradiotherapy (CRT) and bio-radiotherapy (BRT) in patients with head and neck cancer (HNC). Aspiration pneumonia can lead to cancer-related mortality in HNC patients. However, the relationship between aspiration pneumonia occurring during CRT or BRT for HNC and treatment outcomes in HNC patients is not well characterized. In this study, we assessed the influence of aspiration pneumonia on treatment outcomes and sought to identify the clinical risk factors for aspiration pneumonia during definitive CRT and BRT in HNC patients. We retrospectively assessed the data pertaining to patients with locally advanced HNC who received definitive CRT or BRT at the Shizuoka Cancer Center between August 2006 and December 2016. Among the 374 HNC patients who received CRT or BRT, 95 (25.4%) developed aspiration pneumonia during treatment. Aspiration pneumonia was significantly associated with therapeutic response to CRT or BRT (multivariate adjusted odds ratio for complete response, 0.52, p = 0.020) and poor overall survival (multivariate adjusted hazard ratio for overall survival, 1.58, p = 0.024). The multivariate analyses identified four independent factors for aspiration pneumonia: poor oral hygiene, high N-classification, hypoalbuminemia before treatment, and inpatient treatment. Aspiration pneumonia occurring during CRT or BRT has a detrimental effect on the therapeutic response and survival of HNC patients. Careful attention should be paid to these risk factors for aspiration pneumonia in HNC patients undergoing CRT or BRT.
Sections du résumé
BACKGROUND
BACKGROUND
Aspiration pneumonia is one of the most important side effects of chemoradiotherapy (CRT) and bio-radiotherapy (BRT) in patients with head and neck cancer (HNC). Aspiration pneumonia can lead to cancer-related mortality in HNC patients. However, the relationship between aspiration pneumonia occurring during CRT or BRT for HNC and treatment outcomes in HNC patients is not well characterized. In this study, we assessed the influence of aspiration pneumonia on treatment outcomes and sought to identify the clinical risk factors for aspiration pneumonia during definitive CRT and BRT in HNC patients.
METHODS
METHODS
We retrospectively assessed the data pertaining to patients with locally advanced HNC who received definitive CRT or BRT at the Shizuoka Cancer Center between August 2006 and December 2016.
RESULTS
RESULTS
Among the 374 HNC patients who received CRT or BRT, 95 (25.4%) developed aspiration pneumonia during treatment. Aspiration pneumonia was significantly associated with therapeutic response to CRT or BRT (multivariate adjusted odds ratio for complete response, 0.52, p = 0.020) and poor overall survival (multivariate adjusted hazard ratio for overall survival, 1.58, p = 0.024). The multivariate analyses identified four independent factors for aspiration pneumonia: poor oral hygiene, high N-classification, hypoalbuminemia before treatment, and inpatient treatment.
CONCLUSIONS
CONCLUSIONS
Aspiration pneumonia occurring during CRT or BRT has a detrimental effect on the therapeutic response and survival of HNC patients. Careful attention should be paid to these risk factors for aspiration pneumonia in HNC patients undergoing CRT or BRT.
Identifiants
pubmed: 32131771
doi: 10.1186/s12885-020-6682-1
pii: 10.1186/s12885-020-6682-1
pmc: PMC7057640
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
182Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Radiother Oncol. 2010 Oct;97(1):80-5
pubmed: 20223540
N Engl J Med. 2001 Mar 1;344(9):665-71
pubmed: 11228282
Eur Stroke J. 2018 Dec;3(4):347-354
pubmed: 31236482
Gerodontology. 2013 Mar;30(1):3-9
pubmed: 22390255
N Engl J Med. 1993 Oct 28;329(18):1302-7
pubmed: 7692297
BMC Cancer. 2017 Jan 17;17(1):59
pubmed: 28095814
Ann Otol Rhinol Laryngol. 2009 Nov;118(11):811-6
pubmed: 19999368
Strahlenther Onkol. 2003 Jun;179(6):390-5
pubmed: 12789465
Support Care Cancer. 2016 Feb;24(2):953-959
pubmed: 26248650
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61
pubmed: 17467926
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1413-8
pubmed: 16109461
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
BMC Cancer. 2013 Aug 04;13:370
pubmed: 23915314
Oncology. 2016;91(2):78-84
pubmed: 27270420
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205
pubmed: 22749632
Acta Oncol. 2013 Feb;52(2):270-6
pubmed: 23173758
Anticancer Res. 2007 May-Jun;27(3B):1669-72
pubmed: 17595794
Support Care Cancer. 2016 Jul;24(7):3029-36
pubmed: 26887378
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Ann Otol Rhinol Laryngol. 2010 Jun;119(6):391-7
pubmed: 20583737
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8
pubmed: 12007937
J Nutr. 2003 Jan;133(1):336S-340S
pubmed: 12514322
Respir Investig. 2013 Jun;51(2):103-26
pubmed: 23790739
Radiother Oncol. 1997 Apr;43(1):47-51
pubmed: 9165136
Clin Exp Otorhinolaryngol. 2013 Sep;6(3):117-26
pubmed: 24069513
Clin Oncol (R Coll Radiol). 2014 Nov;26(11):697-703
pubmed: 25239671
Radiother Oncol. 2009 Feb;90(2):189-95
pubmed: 19167120
Cerebrovasc Dis. 2016;41(1-2):35-9
pubmed: 26584429
Cancer. 2015 Apr 15;121(8):1303-11
pubmed: 25537836
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544